NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-10-01 20:05இன்று 56 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Syncom Formulations Shareholders Approve Appointment of Rahul Bankda as MD
Syncom Formulations (India) Limited announced shareholder approval at its 38th AGM held on September 30, 2026, for key leadership appointments. Shri Rahul Vijay Bankda has been appointed as Managing Director, effective retroactively from August 12, 2026. Additionally, Smt. Rinki Ankit Bankda was appointed as Whole Time Director effective August 12, 2026, and Smt. Ruchi Jindal was re-appointed as Woman Independent Director for a 5-year term from June 28, 2027.
உச்சம் நம்பிக்கை
என்ன மாறியதுFormal shareholder confirmation of Rahul Vijay Bankda as Managing Director and Rinki Ankit Bankda as Whole Time Director, effective August 12, 2026.
ஏன் இது முக்கியம்Confirms internal succession and board leadership stability within the promoter group for managing ongoing business operations.
AGM Date: 30th செப்டம்பர், 2026Effective Appointment Date: 12th ஆகஸ்ட், 2026Independent Director Term Extension: 5 consecutive years
📅 குறுகிய காலம்Neutral procedural confirmation of management roles already implemented in August 2026; no material stock impact expected.
📈 நீண்ட காலம்Ensures leadership stability and continuity in governance across the company's formulation business.
⚠ அபாய எச்சரிக்கைகள்
Promoter-concentrated executive leadership with close family relationships among top directors.
👀 கவனிக்க வேண்டியவை
Monitor upcoming quarterly results to observe strategic continuity under the confirmed leadership team. Track whether the ongoing expansion efforts translate to steady margin performance.
Promoters Waive ₹4.75 Cr Final FY26 Dividend; Net Outgo Halved to ₹4.65 Cr
Syncom Formulations announced that its Promoters and Promoter Group have voluntarily and unconditionally waived their entitlement to the proposed final dividend of ₹0.10 per share for FY26. Of the total 94,00,00,000 equity shares, promoters hold 47,53,47,599 shares (approx. 50.57%), resulting in a waiver of ₹4.75 crore. Consequently, the total dividend payout will decrease from ₹9.40 crore to ₹4.65 crore, preserving cash within the business. The dividend remains subject to shareholder approval at the upcoming AGM.
உச்சம் நம்பிக்கை
என்ன மாறியதுPromoters have waived their share of the FY26 final dividend, reducing the cash outflow for the dividend by ₹4.75 crore.
ஏன் இது முக்கியம்The company retains ₹4.75 crore in internal cash reserves while ensuring public shareholders still receive their ₹0.10 per share distribution.
Dividend per share: ₹0.10Total shares outstanding: 94,00,00,000Promoter shares waived: 47,53,47,599Dividend amount waived: ₹4,75,34,759.90Net final dividend payable: ₹4,64,65,240.10
📅 குறுகிய காலம்Marginally positive sentiment for retail investors who receive their full dividend entitlement while the company retains ~50.6% of the budgeted cash outflow.
📈 நீண்ட காலம்Limited; reflects promoter alignment and incremental cash retention, but total savings of ₹4.75 crore are modest relative to overall net worth.
👀 கவனிக்க வேண்டியவை
Track shareholder voting on the final dividend resolution at the upcoming AGM and monitor how the retained capital is deployed towards ongoing operations or capacity.
58% PAT Growth to ₹24.85 Cr in Q1 FY27; ₹0.10 Dividend Recommended
Syncom Formulations reported a strong Q1 FY27 with Profit After Tax (PAT) rising 58% YoY to ₹24.85 crore, significantly outpacing revenue growth. Total income for the quarter reached ₹133.36 crore, up 8% from ₹122.94 crore in the previous year. The company demonstrated sharp margin expansion, with Profit Before Tax (PBT) surging 59% to ₹32.25 crore. Additionally, the board recommended a final dividend of ₹0.10 per share for FY26, reflecting a 10% payout on face value.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company achieved a significant jump in profitability and margins in Q1 FY27 compared to the same period last year, despite relatively modest top-line growth.
ஏன் இது முக்கியம்The results indicate strong operating leverage and successful brand positioning in high-margin segments like IVF and Gynaecology, where its Ovafresh brands are leaders.
Q1 PAT Growth: 58%Q1 வருவாய்: ₹125.53 கோடிPBT Margin: 24.2%Dividend per share: ₹0.10Q1 வருவாய் vs TTM வருவாய்: ~1.0%
📅 குறுகிய காலம்The stock is likely to react positively to the sharp earnings beat and the dividend recommendation in the coming days.
📈 நீண்ட காலம்The company's focus on an ethical, prescription-led model and expansion into specialized domestic divisions provides a structural growth path, though it remains a small-cap player in a competitive market.
⚠ அபாய எச்சரிக்கைகள்
Heavy reliance on Pharma segment (98.8% of revenue)
Vulnerability to API price spikes affecting production costs
👀 கவனிக்க வேண்டியவை
Monitor the sustainability of the improved 24.2% PBT margin in upcoming quarters and track the progress of the commercial property acquisition from HDFC Bank intended for infrastructure expansion.
Resignation of Whole-Time Director Kedarmal Shankarlal Bankda Effective August 11, 2026
Syncom Formulations (India) Limited has announced the resignation of Mr. Kedarmal Shankarlal Bankda (DIN: 00023050) from his position as Whole-Time Director, effective August 11, 2026. The resignation letter was received by the company on August 8, 2026, at 10:35 AM. The company stated the departure is intended to facilitate timely succession planning and to allow the director to focus on health and well-being. This change occurs as the company manages a TTM revenue of ₹12,539 cr and maintains a high ROCE of 27.0%.
உச்சம் நம்பிக்கை
என்ன மாறியதுMr. Kedarmal Shankarlal Bankda has stepped down as a Director and Whole-Time Director of the company.
ஏன் இது முக்கியம்As a Whole-Time Director, his departure is significant for executive leadership; however, the company has framed this as a planned succession to ensure an orderly transition of responsibilities.
Effective Date of Resignation: ஆகஸ்ட் 11, 2026TTM வருவாய்: ₹12,539 கோடிMarket Capitalization: ₹30,164 கோடிPharma Segment Growth (YoY): 30.5%Promoter Holding: 50.57%
📅 குறுகிய காலம்The market is likely to view this as a routine management transition given the explicit mention of succession planning and health reasons.
📈 நீண்ட காலம்The long-term impact depends on the quality of the successor and their ability to maintain the current 15.1% operating profit margins and high growth rates.
⚠ அபாய எச்சரிக்கைகள்
Key management personnel transition
High reliance on Pharma segment (98.8% of revenue)
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's upcoming announcements regarding the appointment of a new Whole-Time Director to ensure leadership continuity in the core pharmaceutical formulations segment.
Syncom Formulations Announces Major Leadership Succession; New MD and CFO Appointed
Syncom Formulations has implemented a comprehensive leadership transition effective August 12, 2026, as part of a planned succession strategy. Shri Rahul Vijay Bankda, who has 23 years of experience and previously served as CFO, has been elevated to Managing Director. Simultaneously, Shri Ankur Vijay Bankda, also with 23 years of experience, has been appointed as the new Chief Financial Officer. These changes follow the resignations of the outgoing Managing Director and Whole-time Director, ensuring the next generation of the promoter group takes over key executive functions.
உச்சம் நம்பிக்கை
என்ன மாறியதுA generational shift in the promoter-led management team, with new appointments for the Managing Director, CFO, and Whole-time Director roles.
ஏன் இது முக்கியம்Leadership continuity is vital for the company's expansion plans and maintaining its 15.1% operating margins. The transition appears orderly and involves internal family members with significant tenure.
New MD Experience: 23 yearsNew CFO Experience: 23 yearsPromoter Holding: 50.57%TTM வருவாய்: ₹12539 கோடி
📅 குறுகிய காலம்The market is likely to view this as a routine succession; no immediate impact on stock price is expected unless strategic shifts are announced.
📈 நீண்ட காலம்The transition to a younger leadership team with decades of internal experience suggests a focus on long-term stability and scaling the core pharma formulations business.
⚠ அபாய எச்சரிக்கைகள்
Key person risk during transition
Concentration of key roles within the promoter family
👀 கவனிக்க வேண்டியவை
Investors should monitor if the new leadership maintains the company's current growth trajectory (30.5% YoY in Pharma) and high ROCE of 27.0%.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Syncom Formulations Q1 Net Profit Jumps 56% YoY to ₹24.59 Cr
Syncom Formulations (India) Limited reported a strong start to FY27 with a 56.3% YoY increase in Net Profit to ₹24.59 Cr for the quarter ended June 30, 2026. While revenue from operations grew a modest 7% YoY to ₹124.66 Cr, the company achieved significant margin expansion, with Profit Before Tax (PBT) margins rising to 24.1% from 16.5% in the year-ago period. The core Pharmaceuticals segment remains the primary driver, contributing over 99% of total segment revenue. Additionally, the company restated its EPS for prior periods to comply with Ind AS 33, shifting from a Total Comprehensive Income-based to a Profit After Tax-based calculation.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported a sharp increase in profitability and margin expansion for Q1 FY27, alongside a technical restatement of its EPS calculation methodology to align with Ind AS 33.
ஏன் இது முக்கியம்The significant jump in net profit despite single-digit revenue growth indicates improved operational efficiency and potentially better product mix or pricing power in the core formulations business.
Q1 Net Profit: ₹24.59 கோடிQ1 Revenue from Operations: ₹124.66 கோடிPBT Margin: 24.1%Pharma Segment Revenue: ₹131.36 கோடிRestated EPS (Q1): ₹0.26
📅 குறுகிய காலம்The stock is likely to react positively in the short term due to the substantial bottom-line growth and margin improvement exceeding revenue growth rates.
📈 நீண்ட காலம்The company's ability to maintain high margins in the competitive generic drug market and successfully scale its Pithampur manufacturing operations will be critical for long-term value creation.
⚠ அபாய எச்சரிக்கைகள்
High revenue concentration in the Pharmaceuticals segment (99%)
Sensitivity to API price fluctuations which could impact currently expanded margins
👀 கவனிக்க வேண்டியவை
Investors should monitor the sustainability of these expanded margins in the pharmaceutical segment and watch for updates regarding the operationalization of the commercial property acquired from HDFC Bank to support growth.
Rs 0.10 Dividend: Syncom Formulations Sets September 23, 2026, as Record Date
Syncom Formulations (India) Limited has fixed September 23, 2026, as the record date for a final dividend of Rs 0.10 per equity share (10% of face value) for FY 2025-26. The dividend is subject to shareholder approval at the 38th Annual General Meeting (AGM) scheduled for September 30, 2026. The company reported a TTM PAT of Rs 1,720 Cr, and the proposed dividend represents a yield of approximately 0.69% at the current price of Rs 14.5. Uniquely, the company has provided a dividend waiver option for shareholders until September 26, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has established the formal timeline for its annual dividend distribution and shareholder meeting for the 2025-26 financial year.
ஏன் இது முக்கியம்While the dividend yield is modest at ~0.69%, the payout confirms the company's ability to distribute profits despite its focus on high growth (28% expected) and infrastructure expansion.
📅 குறுகிய காலம்The stock is likely to trade flat to slightly positive leading up to the ex-dividend date, though the small dividend amount typically limits price volatility.
📈 நீண்ட காலம்Limited structural impact from this routine filing; the long-term value depends on the company's ability to maintain its 15.1% OPM and scale its pharma formulations business.
👀 கவனிக்க வேண்டியவை
Investors should ensure their holdings are in their demat accounts by the record date of September 23, 2026, to be eligible for the dividend. Monitor the AGM proceedings on September 30 for updates on the Pithampur manufacturing setup and the HDFC Bank property acquisition.
CFO Resignation: Rahul Vijay Bankda to step down effective August 11, 2026
Syncom Formulations (India) Limited has announced the resignation of its Chief Financial Officer (CFO), Mr. Rahul Vijay Bankda, effective August 11, 2026. The resignation was formally received by the company on August 8, 2026. This change in Key Managerial Personnel (KMP) occurs as the company manages a TTM revenue of Rs 12,539 Cr. No successor has been named in the current disclosure, making the transition period important for financial oversight.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company's Chief Financial Officer (CFO) has resigned from his position.
ஏன் இது முக்கியம்The CFO is a critical Key Managerial Personnel responsible for financial strategy and compliance; a smooth transition is necessary to maintain investor confidence in the company's financial management.
Effective date of resignation: 11th ஆகஸ்ட், 2026TTM வருவாய்: Rs 12,539 கோடிTTM PAT: Rs 1,720 கோடிPromoter Holding: 50.57%
📅 குறுகிய காலம்Neutral; the market typically monitors KMP exits for any signs of internal friction, but immediate impact is usually limited unless a successor is not found.
📈 நீண்ட காலம்Limited; the company's long-term trajectory depends on its ability to sustain its 30.5% YoY growth in the Pharma segment and manage its high valuation.
⚠ அபாய எச்சரிக்கைகள்
Succession risk
👀 கவனிக்க வேண்டியவை
Monitor the company's upcoming filings for the appointment of a new CFO to ensure continuity in financial leadership and reporting.
Syncom Formulations FY26 Net Profit Surges 55% to ₹76 Cr; EPS Rises to ₹0.81
Syncom Formulations (India) Limited reported a robust 55.5% year-on-year increase in Net Profit to ₹76.01 crore for the fiscal year ended March 31, 2026. While annual revenue from operations grew a modest 5.1% to ₹486.57 crore, the company saw a substantial jump in Profit Before Tax, which rose to ₹100.53 crore from ₹64.66 crore. Earnings Per Share (EPS) improved significantly to ₹0.81 from ₹0.52. The company also noted a minor impact of ₹87.81 Lacs due to the implementation of new labour codes.
முக்கிய அம்சங்கள்
Net Profit for FY26 rose 55.5% YoY to ₹76.01 crore from ₹48.87 crore in FY25.Annual Revenue from operations increased to ₹486.57 crore compared to ₹462.85 crore in the previous year.Profit Before Tax (PBT) surged to ₹100.53 crore, crossing the ₹100 crore milestone for the first time.Full-year EPS increased to ₹0.81 compared to ₹0.52 in the prior fiscal year after accounting for restatements.The Pharmaceuticals segment remains the dominant contributor, generating ₹512.74 crore in gross segment revenue.
👀 கவனிக்க வேண்டியவை
The sharp increase in profitability despite modest revenue growth indicates strong operational leverage and margin improvement. Investors should maintain a positive outlook while monitoring if the company can accelerate revenue growth in the coming quarters.
Syncom Formulations Acquires Mumbai Commercial Property for ₹57.26 Crore
Syncom Formulations (India) Limited has successfully completed the acquisition of a significant commercial property in Mumbai. The company purchased the entire 7th floor of 'Trade Star' in Andheri (East) from HDFC Bank Ltd. The total consideration for this material acquisition amounted to ₹57.26 crore, which has been paid in full. This move represents a substantial investment in corporate infrastructure and fixed assets.
முக்கிய அம்சங்கள்
Acquired the entire 7th Floor of Trade Star building on Andheri-Kurla Road, MumbaiTotal transaction value of ₹57.26 crore paid to HDFC Bank LtdAcquisition completed following a successful bid processDisclosed as a material event under Regulation 30 of SEBI (LODR) Regulations
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's upcoming balance sheet to see how this ₹57.26 crore cash outflow affects liquidity versus asset growth. This acquisition indicates a strong commitment to expanding corporate presence in a prime business hub.
Syncom Formulations Q3 Net Profit Rises 47% YoY to ₹18.86 Cr; Margins Expand
Syncom Formulations (India) Limited reported a strong bottom-line performance for Q3 FY26, with net profit rising 47.4% YoY to ₹18.86 crore. This growth comes despite a 9.8% YoY decline in revenue from operations, which stood at ₹114.59 crore. The profitability surge was largely due to a sharp 37.8% reduction in raw material costs, significantly improving operating margins. Additionally, the company is facing a legal challenge regarding a ₹5.44 crore GST demand, which it plans to appeal.
முக்கிய அம்சங்கள்
Standalone Net Profit increased 47.4% YoY to ₹18.86 crore from ₹12.79 crore.Revenue from operations declined 9.8% YoY to ₹114.59 crore compared to ₹127.03 crore.Raw material costs decreased significantly to ₹47.45 crore from ₹76.26 crore YoY, driving margin expansion.Basic and Diluted EPS improved to ₹0.23 from ₹0.14 in the corresponding quarter last year.Company disclosed a legal contest against a ₹5.44 crore GST demand involving ineligible Input Tax Credit.
👀 கவனிக்க வேண்டியவை
Investors should focus on the significant margin improvement driven by lower input costs, while monitoring if the company can reverse the slight decline in top-line revenue. The pending GST litigation is a minor risk but should be tracked for potential impact on future cash flows.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
